circulating monocytes that infiltrate the tumor and differentiate into macrophages. [8] [9] [10] [11] Here, we review literature on the role of TAMs in the development of tumor.
Activation of Macrophages-M1 and M2 Polarization
Mononuclear phagocytes are versatile cells that can express different functional programs in response to microenvironmental signals 12 that are typically manifested in pathological conditions such as infections and cancer. 13, 14 There are 2 major pathways to produce macrophage activation in vivo. These include the M 1 (or classical) macrophage activation and the M 2 activation program. Classic or M 1 macrophage activation occurs in response to microbial products or interferon-γ and is characterized by high interleukin-12 (IL-12) and IL-23 production. 15 It activates polarized type I response and is characterized by high capacity to present antigen and to produce factors that promote T-cell proliferation and activity. This activation also results in high production of toxic intermediates such as NO and reactive oxygen intermediates (ROIs). Thus, the M1 macrophage can serve as a potent effector cell that kills microorganisms and tumor cells, presents antigens, and produces large amounts of proinflammatory cytokines. 13 TAMs located in the tumor microenvironment exhibit M2 polarization. Exposure to glucocorticoid hormones IL-10 and IL-13 in tumors induces TAMs to develop into polarized type II (alternatively activated) or M 2 macrophages. These cells have poor antigen-presenting capability, produce factors that suppress T-cell proliferation and activity, and are generally better adapted to scavenging debris, promoting angiogenesis, and repairing and remodeling wounded/damaged tissues. M acrophages are a part of the mononuclear phagocyte system and are professional antigenpresenting cells for adaptive immunity. Mononuclear phagocytes migrate out from bone marrow, circulate briefly in the blood as monocytes, and then enter into the tissues and inflammatory foci where they differentiate into macrophages. 1 Compelling evidence has emerged over the past decades for macrophages playing an important role in the defense against harmful microorganisms and tumor cells.
Activation of macrophages has been an attractive approach in the development of cancer therapy. [2] [3] [4] [5] Indeed, evidence from many studies suggests that activated macrophages are capable of selectively lysing tumor cells in vitro and play an important role in the immune-mediated destruction of tumor cells in vivo. [5] [6] [7] For the macrophages to exhibit cytotoxic function, they require stimulation either with bacterial cell wall products such as lipopolysaccharide (LPS) or muramyl dipeptide or with cytokines such as interferon-γ (IFN-γ) and granulocyte-macrophage colony-stimulating factor (GM-CSF). Activated macrophages secrete several substances that are directly involved in tumor cell killing, that is, tumor necrosis factor (TNF) and nitric oxide (NO). However, macrophages in the tumor microenvironment, collectively called tumor-associated macrophages (TAMs), secrete substances that are capable of stimulating tumor cell growth, depending on the stage and nature of the tumor. These cells are derived from Tumor Versus Tumor-Associated Macrophages: How Hot is the Link?
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One of the functions of macrophages is to provide a defense mechanism against tumor cells. In contrast, tumor-associated macrophages (TAMs), which represent the major inflammatory component of the stroma of many tumors, are associated with tumor progression and metastasis. TAMs, in contrast with normal macrophages, exhibit the M2 phenotype, and thereby exhibit pro-tumoral functions, including angiogenesis and matrix remodeling. This review will discuss the role of TAMs in tumor progression and provide an overview of their significant part in tumor metastasis and angiogenesis.
Keywords: tumor-associated macrophages; angiogenesis; metastasis; natural products M 1 macrophages express opsonic receptors (such as FcγRIII [CD16]) when exposed to classic activation signals such as IFN-γ and LPS. In contrast, M 2 macrophages express preferentially nonopsonic receptor (eg, mannose receptor) and scavenger receptor. M 1 macrophages exhibit arginine metabolism and give rise to high levels of inducible NO synthase (iNOS; NOS2), whereas M 2 macrophages express a predominant activation of the arginase pathway and the consequent production of ornithine and polyamines. This metabolic switch occurs preferably during the activation of the M 2 a and M 2 c polarization programs. 16 The M 1 macrophages are characterized by an IL-12 high and IL-10 low phenotype, whereas M 2 macrophages are characterized by an IL-10 high and IL-12 low phenotype. 17 Tumor-associated macrophages are poor producers of NO 18 and are shown to be poor producers of ROIs. 19 Nuclear factor-κB (NFκB) activation results in promoting the transcription of several proinflammatory genes. Sica and his coworkers 20 reported that TAMs display defective NFκB activation. Mantovani and his coworkers 12 reported that TAMs express low levels of inflammatory cytokines such as IL-12, IL-1β, TNF-α, and IL-6. Thus, TAMs resemble M 2 macrophages in terms of cytotoxicity and expression of inflammatory cytokines. TAMs release a spectrum of products that is skewed to a tumorpromoting and immunosuppressive type. Accordingly, TAM products act in 2 ways to support tumor progression, on the one hand supporting tumor growth, angiogenicity, and extracellular matrix (ECM) degradation, and on the other hand, suppressing potential antitumor immune activities.
Role of TAMs in Tumor Growth
Tumor-associated macrophages have been studied extensively for their relationship with tumor cells and their multifaceted functions in the tumor microenvironment. In breast tumors, TAMs are diffusely distributed throughout the tumor and reside in tumor zones and tumor edges, around ductal areas, and in the tumor stromal areas. 21, 22 Also in breast carcinomas, an intensive TAM accumulation was noted in necrotic areas within the tumor. [23] [24] [25] [26] TAMs have the ability to both positively and negatively regulate tumor growth 13 ; tumor cell cytostasis may be induced, but in contrast tumor cell survival may be promoted by macrophage activation and release of angiogenic and mitogenic cytokines in the tumor microenvironment such as vascular endothelial growth factor (VEGF), 27 proinflammatory cytokines, and enzymes. 28, 29 TAMs produce a wide range of growth factors, including platelet-derived growth factor (PDGF), epidermal growth factor, and transforming growth factor (TGF)-β, as well as cytokines such as interleukin-1 and TNF-α, that have been shown to enhance tumor metastasis in various in vivo models. [30] [31] [32] [33] Accordingly, macrophages when co-cultured with tumor cells have been shown to secrete substances that can stimulate tumor cell proliferation. 34, 35 Supporting this, macrophage depletion studies have also shown that the presence of TAMs is essential for the growth of tumors. 36 Tumors produce monocyte chemoattractant protein-1 (MCP-1) and colony stimulating factor-1 (CSF-1), which are known chemoattractants for monocytes/macrophages. It is known that the extent of MCP-1 expression in human cancers is correlated with both TAM infiltration and tumor malignancy 37 and that the genetic deletion of CSF-1 in the PyMT mouse model of breast cancer dramatically decreased TAM infiltration and attenuated tumor progression to metastasis. 38, 39 Another possible mechanism by which TAMs favor tumor growth is through the production of ornithine and polyamines. 40 L-arginine is the substrate molecule for macrophage biosynthesis of the cytotoxic molecule NO through the activity of the inducible form of the nitric oxide synthase (iNOS). Tumors markedly inhibit intratumoral macrophage production of NO 18 by shunting L-arginine metabolism in favor of the biosynthesis of ornithine, 40 a precursor for polyamine synthesis and a key factor required for tumor cell proliferation.
Still another possible mechanism by which TAMs favor tumor growth is through limited cytotoxicity. There are various studies that report that macrophages mediate tumor cell killing through the production of TNF-α, IL-1, and IL-6 secretion. 41 However, a very low number of TAMs producing TNF-α has been observed (as well as interleukin-2 and -12, 42 cytokines that can increase the tumoricidal capacity of natural killer [NK] cells). However, TAMs have been shown to produce higher levels of IL-10, which in turn can inhibit T helper (TH1) activity with resultant suppression of cytotoxic T-cell generation and activity, as well as inhibition of NK and lymphokine-activated killer cell cytotoxicity. 20, 43 
Role of TAMs in Invasion and Metastasis
The major clinical challenge of cancer therapy remains the eradication (or prevention) of metastatic disease. A principal barrier to destruction of disseminated cancer is the heterogenous nature of cancer, that is, tumors contain subpopulations of cells that are able to subvert host defenses and recruit infiltrating cells that supply needed growth factors and blood supply. 44, 45 Mounting lines of evidence also implicate TAMs in the regulation of metastasis. 34 Wyckoff and his coworkers 46 demonstrated a synergistic relationship between breast tumor cells and macrophages in cell migration and suggested a role for TAMs in metastasis. High numbers of TAMs in primary tumors have been correlated with early establishment of metastasis in a number of tumor types. 31, 47 The distinct microenvironments where TAMs act include areas of invasion where TAMs promote cancer cell motility: stromal and perivascular areas where TAMs promote metastasis. Hagemann et al 48 reported that co-culturing macrophages with tumor cells enhances their invasive properties in a manner dependent on TNF-α and matrix metalloproteinases (MMP). Subsequently, it was shown in Matrigel invasion assays that this invasive potential in macrophages is through the activation of c-Jun-NH2-kinase and nuclear factor-κB signaling pathways. 49 Among the enzymes responsible for destroying the basement membrane and extracellular matrix are matrix metalloproteinase-2 (MMP-2, gelatinase A, type IV collagenase) and MMP-9 (gelatinase B, type IV collagenase). The degradation of the basement membrane and extracellular matrix provides a microenvironment in which activated endothelial cells can proliferate and migrate to form new blood vessels. Increased expression of MMP-2 and MMP-9 was found in several tumor types. 50, 51 Expression of MMP-2 and MMP-9 by host stromal cells, including macrophages, correlated with the depth of tumor invasion and histological grade in endometrial carcinoma. 51 Direct evidence has been presented that MMP-9 derived from hematopoietic cells of host origin contributes to skin carcinogenesis. 52 TAMs have been shown to produce MMP-2 and MMP-9 and thereby help in the degradation of proteins of the extracellular matrix, and also to produce activators of MMPs, such as chemokines. 53 Chemokines have been shown to induce gene expression of various MMPs and, in particular, MMP-9 production along with the uPA receptor. 54 Studies using mouse sarcomas have shown that TAMs produce increased amounts of neutral serine protease, a plasminogen activator. 55 Tumor cells can express receptors for plasminogen activator. Thus, macrophage-derived proteases may contribute to tissue invasion and spread of tumor cells.
Role of TAMs in Angiogenesis
The angiogenesis process involves several cell types and mediators, which interact to establish a specific microenvironment suitable for the formation of new capillaries from preexisting vessels. Considerable evidence indicates that TAMs play an important role in regulating angiogenesis. A positive correlation between macrophage infiltration and angiogenesis has been reported in various cancers. 22, 32, 39, [56] [57] [58] [59] [60] [61] In the tumor microenvironment, the stage of the tumor growth determines the role of TAMs. In the early stages of tumor growth, the presence of TAMs will delay the tumor cell proliferation. But when the tumor grows beyond the size of 1 to 2 cm 3 , it requires the adequate supply of oxygen and nutrients for tumor cell expansion and spread. [62] [63] [64] During this stage, TAMs significantly contribute to tumor progression by secretion of angiogenic factors. Furthermore, as macrophages are phagocytes, they may also be attracted into hypoxic, perinecrotic areas along a trail of necrotic debris emanating from such areas. Hypoxia seems to inhibit macrophage migration, thereby immobilizing them in such areas. Hypoxic areas of tumors produced by inadequate vascular perfusion are likely to generate additional adverse conditions in the tumor microenvironment, such as low pH and elevated levels of lactate, which might stimulate proangiogenic gene expression in TAMs. 65, 66 The hypoxic (low oxygen tension) condition in the tumor microenvironment promotes TAMs adapted to hypoxia, which is achieved by the increased expression of hypoxiainducible and proangiogenic genes, such as VEGF, pFGF, and CXCL 8, as well as glycolytic enzymes, whose transcription is controlled by transcription factors HIF-1 and HIF-2. [67] [68] [69] [70] [71] TAMs have been shown to accumulate in hypoxic/necrotic areas in human endometrial, breast, prostate, and ovarian carcinoma. 24, 31, [72] [73] [74] In lung cancer, TAM may favor tumor progression by contributing to stroma formation and angiogenesis through their release of PDGF, in conjunction with TGF-β1 production by cancer cells. 13 The elevated expression of VEGF and endothelin (ET-2) has been observed in hypoxia. 23, 75, 76 Indeed, ET-2 and VEGF were shown to induce migration of cells belonging to the monocyte/macrophage lineage. 77 Various inhibitors of hypoxia-responsive transcription factor HIF-1α such as farnesyl transferase inhibitors (P13K inhibitors) are now in clinical trials. 78 Additional studies are needed to clarify this part and to understand whether HIF activity may play different roles in the activation of TAMs.
TAMs produce a wide array of proangiogenic molecules and matrix-remodeling factors, including CXCL8, VEGF, FGF, PDGF, TNF-α, MMPs, and urokinase-type plasminogen activator (uPA), 31, [79] [80] [81] [82] but it remains to be clarified how important these TAM-secreted factors are in the economy of tumor angiogenesis, because many proangiogenic molecules are also produced by other components of the tumor stroma and by the tumor cells themselves.
Still another possible mechanism through which TAMs contribute to the angiogenic activity is through enhanced fibrin deposition via procoagulant activity, 83 and this area requires further investigation.
Recently, Bingle and his coworkers 58 demonstrated that macrophages present within a solid tumor significantly contribute to the initiation of angiogenesis. However, in the absence of macrophages, tumor cells produce the necessary stimuli to initiate tumor angiogenesis but initiation is delayed. Thus, the presence of macrophages in the tumor microenvironment contributes to tumor cell dissemination and metastasis by promoting angiogenesis.
Targeting TAMs Using Natural Products
Natural products have been traditionally accepted as remedies due to the popular belief that they produce few adverse side effects. Therefore, understanding the potential beneficial or adverse influence of natural products extensively used by human population is important in implementing public health safety measures.
So far very few natural products have been reported to possess effects on TAMs. Recently we reported that the methanolic extract of Biophytum sensitivum could inhibit nitrite and cytokine (IL-1β, TNF-α, GM-CSF, and IL-6) production in TAMs. 84 Rutin, a member of the flavone family, has been shown to regulate the expression of VEGF, IL-1β, and TNF-α in TAMs. 85 Some of the inhibitors of HIF-1α (eg, farnesyl transferase inhibitors, P13K inhibitors) are now in clinical trials. 78 More recently it was shown that legumain, a member of the asparaginyl endopeptidase family functioning as stress protein, overexpressed by TAMs, provides an ideal target molecule for developing novel drugs with much therapeutic efficacy. 86 To summarize, TAMs can affect tumor growth both positively and negatively. They can enhance tumor growth by promoting tumor cell proliferation, metastasis, and angiogenesis. The outcome of the competing interactions between TAMs and tumor cells in the tumor microenvironment is still poorly understood. Further studies, therefore, are required to define more precisely these complex interactions between the TAMs and tumor cells. A better understanding of the regulation and function of TAMs may help to establish novel therapies for cancer management.
